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Abstract
Introduction: Mortality in systemic lupus erythematosus (SLE) patients is influenced by an increased occurrence of
severe cardiovascular complications. Statins have been proven to protect a wide spectrum of SLE patients from
these complications. This study was conducted to determine the possible efficacy of atorvastatin in SLE patients as
assessed by multi-detector computed tomography (MDCT)-based coronary calcium scoring and single photon
emission computed tomography (SPECT) of the myocardium.
Methods: Sixty SLE patients in stable clinical conditions were randomized to receive either atorvastatin (40 mg
daily; n = 28) or placebo (n = 32). Clinical and biochemical evaluation together with MDCT-based coronary calcium
scoring and SPECT studies (Tc-99 m sestamibi) were performed at the time of randomization and after 1 year of
treatment.
Results: At randomization, SPECT revealed perfusion defects at rest in 22 (36.7%) patients and exercise-induced
defects in 8 (13.3%), whereas MDCT revealed coronary calcifications in 15 subjects (25%). Coronary calcium deposits
increased after 1 year in the placebo group (plaque volume change from 35.2 ± 44.9 to 62.9 ± 72.4, P < 0.05;
calcium score from 32.1 ± 39.1 to 59.5 ± 64.4; P < 0.05), but not in the atorvastatin group (plaque volume 54.5 ±
62.4 vs. 51.0 ± 47.6, P not significant; calcium score 44.8 ± 50.6 vs. 54.9 ± 62.5, P not significant). The atorvastatin
group showed a decrease in total serum cholesterol (from 5.1 ± 1.2 to 4.4 ± 0.7 mmol/L, P < 0.05), LDL cholesterol
(2.9 ± 1.0 to 2.3 ± 0.6 mmol/L, P < 0.05), triglycerides (1.6 ± 0.6 to 1.2 ± 0.5 mmol/L, P < 0.05), and C-reactive
protein (CRP) (4.4 ± 4.1 to 2.7 ± 1.7 mg/L, P < 0.05). There was no change in the mean Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) score in patients from both groups. Perfusion defects observed at
randomization showed no change after one year treatment with atorvastatin.
Conclusions: In SLE patients 40 mg of atorvastatin daily for 1 year led to a decrease in serum lipids and CRP
levels. Additionally the progression of atherosclerosis, as assessed by MDCT-based coronary calcium scoring, is
restrained by atorvastatin treatment. The value of statin treatment in patients with SLE free from cardiovascular
disease clinical symptoms should be addressed in large, prospective clinical trials.
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Systemic lupus erythematosus (SLE) is a generalized
autoimmune disease, in which diffuse, chronic inflam-
matory reactions play an important pathogenic role.
Contemporary mortality of SLE patients is mainly due
to severe cardiovascular complications [1]. Suggested
factors that may influence accelerated arteriosclerosis
include a generalized, chronic inflammation and corti-
costeroid usage [2]. The relation between increased
levels of inflammatory cytokines and life-threatening
cardiovascular episodes has been well-documented [3].
However, the optimal strategy for the prevention of
atherosclerosis in SLE patients is not established.
Statins, HMG-CoA reductase inhibitors, are widely
used in the treatment of hyperlipidemia and prevention
against cardiovascular disease. In the general population,
large randomized controlled trials have demonstrated
their beneficial effects in hypercholesterolemia treatment
[4], as well as primary and secondary prevention of cor-
onary artery disease [5-7] with the regression of estab-
lished coronary atherosclerosis [8]. Interestingly, the
magnitude of the protection and decrease in mortality
afforded by statins cannot be explained entirely by their
cholesterol-lowering effect. It has been shown, among
others, that statins exert strong anti-inflammatory action
[9] and ameliorate endotheliald y s f u n c t i o n ,p r o t e c t i n g
from inflammation-induced endothelial injury [10,11].
Statins are recommended for patients with SLE at high
cardiovascular risk with diagnosed coronary artery dis-
ease, but these recommendations are based on the
extrapolation of the results obtained in non-SLE popula-
tions [12-16]. There has been little evidence for the
effectiveness of statins in cardiovascular symptom-free
SLE patients. Implementation of multi-detector com-
puted tomography (MDCT) and single photon emission
computerized tomography (SPECT) allows for a non-
invasive evaluation of coronary atherosclerosis and myo-
cardial perfusion abnormalities, and enables the assess-
ment of statin influence on coronary artery structural
changes and heart function.
This study was conducted to determine the effect of
atorvastatin treatment on MDCT-based coronary cal-
cium scoring and SPECT-assessed myocardial perfusion
abnormalities in SLE patients free of clinical symptoms
of cardiovascular disease.
Materials and methods
The study was performed in 60 consecutive patients
treated for systemic SLE in the Department of Internal
Medicine, Jagiellonian University Medical College, Kra-
kow. All patients fulfilled at least four American College
of Rheumatology classification criteria for SLE [17,18]
and were in stable clinical conditions (no need for
immunosuppressive therapy intensification, i.e. current
immunosuppressive drug dose increase or introduction
of an additional immunosuppressive drug within the
past three months). Patients with known cancer, clinical
symptoms of coronary heart disease or heart failure
(New York Heart Association III or IV class), renal fail-
ure (creatinine clearance < 30 ml/min), and/or respira-
tory failure were excluded from the study.
Atorvastatin was chosen for this study because of its
superiority over two other statins (simvastatin and pra-
vastatin) in the inhibition of atherosclerosis shown by
two large clinical trials [19,20]. We chose, however, a
daily dose of 40 mg to limit treatment-associated
adverse events.
Patients were randomized (random option in Micro-
soft Excel software, Qumak Secom SA, Warsaw, Poland)
to atorvastatin (40 mg, in the evening) or placebo group.
Placebo group received shape and color-matched pla-
cebo tablets at the same time. The duration of the study
was one year. All parameters described below were
assessed at randomization and after one year of treat-
ment by medical staff, unaware of the type of treatment.
The SPECT study (ECAM Gamma Camera, Siemens,
Munich, Germany) was performed at rest and during
exercise in a two-day protocol. At the first day, at near
maximal stress, a 25 to 40 mCi dose of Tc-99 m sesta-
mibi was injected (actual patient dose was modified tak-
ing into account patients weight) and exercise continued
for one additional minute after injection. Tc-99 m sesta-
mibi SPECT imaging was begun 15 to 30 minutes later.
On the second day rest examinations were performed.
SPECT was performed using a circular 180° acquisition
for 60 projections at 20 seconds per projection. Myocar-
dial perfusion was assessed in 17 left ventricle myocar-
dial segments. The number of segments with persistent
or exercise-induced perfusion defects were assessed by
visual interpretation.
Coronary calcium scoring was performed using a mul-
tidetector CT imager (Somatom Definition, Siemens,
Munich, Germany). The images were ECG triggered
with 3 mm thick sections obtained covering the whole
heart. Coronary artery calcifications were defined as
lesions with attenuation greater than 130 HU in more
than four adjacent pixels. For the quantification of cor-
onary calcium 3D Leonardo application (Siemens,
Munich, Germany) was used. The number of athero-
sclerotic plaques in particular coronary arteries and its
volume were assessed. The Agatson calcium score was
calculated [21].
Laboratory tests included determination of serum anti-
nuclear antibodies (ANA) presence, their titer (indirect
immunofluorescence; Hep-2 cells; Euroimmun GmbH,
Lubeck, Germany) and type (immunoblotting; Euroline
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concentrations of C-reactive protein (CRP), and comple-
ment C3c and C4 components by nephelometry (Sie-
mens, Munich, Germany).
In addition, serum levels of anticardiolipin (aCL) and
antib2GPI antibodies (of both, IgG and IgM class) were
measured using home-made ELISA with the Sapporo
standard for antib2GPI antibody measurements (HCAL
for IgG, EY2C9 for IgM), as previously described [22].
The values exceeding 99
th percentile of a healthy popu-
lation sample were considered positive.
Lupus anticoagulant (LA) was determined in accor-
dance with the three-step procedure recommended by
the International Society on Thrombosis and Haemosta-
sis [23].
Statistical analysis was performed using Statistica Six
Sigma software (StatSoft, Krakow, Poland). All numeri-
cal data were expressed as mean values ± standard
deviations, as median values or as proportions. Continu-
ous variables were compared using a t-test. Chi-square
test was used to examine differences in proportions.
The level for statistical significance was predetermined
at P < 0.05.
Before the study, an informed consent was obtained
from each patient. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki.
The study was approved by the Ethical Committee of
the Jagiellonian University in Krakow, Poland.
Results
The study group consisted of 54 (90%) females and 6
(10%) males, aged 20 to 73 years (mean 41.8 years).
Twenty eight patients formed the atorvastatin group and
32 patients belonged to the placebo group. Three sub-
jects were previously diagnosed with antiphospholipid
syndrome (APS) based on the revised APS classification
criteria [24]. One of these three suffered from an objec-
tively confirmed pulmonary embolism. ECG recordings
were normal in all the patients. Results of peripheral
blood count, serum sodium, potassium, glucose, creati-
nine, and urinalysis were all normal. Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) score
[25] at randomization ranged from 0 to 20 (median 4).
The main complaints at inclusion were arthralgias and
main laboratory abnormalities - low complement levels
and increased ANA titers (four patients were ANA
negative; Table 1). Immunosuppressive treatment
included: methylprednisolone in 32 (53.3%) subjects (≤ 4
mg for clinical stability maintenance), prednisone in 2
(3.3%), chloroquine derivate in 5 (8.3%), azathioprine in
4 (6.7%), cyclophosphamide in 3 (5%), and methotrexate
in 2 (3.3%). The other 12 patients did not use any
immunosuppressive drugs in the past 12 months of
observation. Other treatments included angiotensin con-
verting enzyme inhibitors in 4 (6.7%) subjects, beta
blockers in 3 (5%) and calcium channel blockers in 2
(3.3%). APS patients were treated with anticoagulant
(warfarin, two patients) or antiplatelet therapy (aspirin,
one patient). The above described pharmacotheraphy
remained unchanged during the one-year treatment
period.
Baseline characteristics of the study patients by pla-
cebo/atorvastatin group is shown in Table 2.
During the entire observation period, pathologic
results of SPECT or MDCT were found in 37 (61.6%)
out of 60 patients examined.
At randomization, SPECT study revealed myocardial
perfusion abnormalities in 30 (50.0%) patients, persistent
defects in 22 (36.7%) patients, and exercise-induced
defects in 8 (13.3%). The number of myocardial seg-
ments with persistent defects ranged from two to five
(median three), and with exercise-induced defects from
one to four (median three). Perfusion abnormalities
were observed predominantly in the region supplied by
the left anterior descending artery (22 patients, 73%),
but also in the right coronary artery (three patients,
10%) or left anterior descending together with right or
circumflex arteries (five patients, 17%). Out of 30
Table 1 Autoantibodies and other laboratory parameters in SLE patients at randomization
Range (mean ± SD) Number (%) of patients with out-of-range values
ANA (titer) 0-1/20480 56 (93.3%)
C3c (g/l) 0.43-1.39 (0.90 ± 0.25) 32 (53.3%)
C4 (g/l) 0.02-0.26 (0.13 ± 0.05) 16 (26.7%)
LA - 11 (18.3%)
aCL IgG (RU/ml) 0.68-121.56 (14.4 ± 20.3) 20 (33.3%)
aCL IgM (RU/ml) 1.62-52.93 (12.1 ± 10.6) 26 (43.3%)
antib2GPI IgG (RU/ml) 0.16-95.33 (3.8 ± 15.3) 8 (13.3%)
antib2GPI IgM (RU/ml) 0.14-21.66 (2.2 ± 3.7) 24 (40%)
aCL, anticardiolipin antibodies; ANA, antinuclear antibodies; antib2GPI, antib2-glycoprotein I antibodies; LA, lupus anticoagulant; SD, standard deviation; SLE,
systemic lupus erythematosus.
Abnormal low levels for C3c: < 0.9 g/l, for C4: < 0.1 g/l. Cut-off value for aCL IgG: > 20 RU/ml, aCL IgM: > 30 RU/ml, antib2GPI IgG: > 3 RU/ml, antib2GPI IgM >
2.6 RU/ml.
Plazak et al. Arthritis Research & Therapy 2011, 13:R117
http://arthritis-research.com/content/13/4/R117
Page 3 of 9patients with perfusion abnormalities, in 21 (70%) the
typical signs of ischemia (horizontal or down-slope ST
depression ≥ 0.1 mV) were visible in ECG recordings
during exercise.
At randomization, MDCT revealed coronary calcifica-
tions in 15 (25%) patients. The number of atherosclero-
tic calcified plaques ranged from 2 to 13 (median 3), its
volume 4 to 156.4 mm
3 (mean 45.5 ± 58.6). Calcium
scores ranged from 2 to 138.9 (mean 39.9 ± 50.9). Calci-
fications were present in left anterior descending artery
(eight patients, 53%), right coronary artery (two patients,
13%), left anterior descending with right coronary artery
(one patient, 7%) or all three arteries (four patients,
27%).
Of the group of patients with any pathology in SPECT
or MDCT at baseline (n = 36, 100%), myocardial perfu-
sion abnormalities accompanied by the presence of cor-
onary calcifications were present in nine (25%) patients.
In 21 (58%) patients, SPECT study was abnormal despite
the lack of coronary calcifications (calcium score = 0).
On the other hand, in six (17%) patients with mild cal-
cium deposits (two to three plaques, calcium score 4.4
to 35.1 (mean 14.8 ± 14.2)) SPECT study did not show
any perfusion defects.
During one-year observation progression of athero-
sclerosis was observed only in the placebo group (Table
3). Out of nine patients with coronary plaques at rando-
mization, the increase of plaque volume (> 10 mm
3)
after one year was observed in five (55.6%). In one
patient free of calcium deposits at randomization, new
plaques appeared after one year. As a result, the mean
coronary plaque volume and calcium score increased
significantly (Table 3). An example of atherosclerosis
progression in a patient from the placebo group is
shown in Figure 1.
In the atorvastatin group, there was no increase of
plaque volume (> 10 mm
3) in any of the six patients
with deposits found at randomization. Also, the mean
coronary plaque volume and calcium score did not
change (Table 3).
The number of patients with perfusion defects and the
number of myocardial segments with persistent or exer-
cise-induced defects in the SPECT study remained
unchanged during one-year observation in neither group
of patients studied (Table 4).
After one year of treatment, total serum cholesterol
decreased promptly by 13%, low-density lipoprotein
(LDL) cholesterol by 21%, triglycerides by 25% and CRP
concentration by 39% in the atorvastatin group, but
remained unchanged in the placebo group (Table 5).
There was no change in the activity of alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
nor creatine phosphokinase (CPK) in either group,
except for one patient in the placebo group (Table 5).
There was no need for atorvastatin discontinuation in
any of the patients.
Mean value of the SLEDAI score remained unchanged
in both groups (Table 5). During the treatment period,
SLE flare (SLEDAI increase ≥ 3) was observed in two
patients from the atorvastatin group and in one from
the placebo group. In two atorvastatin group patients,
t h eS L E D A Ii n c r e a s e( f r o m8t o1 2a n df r o m4t o8
points) resulted solely from the onset of hematuria. In
one patient from the placebo group, SLEDAI increase
Table 2 Baseline characteristics of the study patients by group
Placebo group
(n = 32)
Atorvastatin group
(n = 28)
P
Age (years) 41.4 ± 12.4 41.8 ± 13.4 ns
Gender (females/males) 30/2 24/4 ns
Arterial hypertension (n (%)) 2 (6.3%) 1 (3.6%) ns
Diabetes mellitus (n (%)) 0 (0%) 0 (0%) ns
Obesity (n (%)) 0 (0%) 0 (0%) ns
Tobacco smoking (n (%)) 1 (3.1%) 1 (3.6%) ns
Total cholesterol (mmol/l) 4.5 ± 0.8 5.1 ± 1.2 ns
LDL cholesterol (mmol/l) 2.6 ± 0.8 2.9 ± 1.0 ns
HDL cholesterol (mmol/l) 1.4 ± 0.3 1.4 ± 0.3 ns
Triglycerides (mmol/l) 1.2 ± 0.5 1.6 ± 0.6 < 0.05
CRP (mg/l) 4.0 ± 8.9 4.4 ± 4.1 ns
Number of patients with plaques in MDCT (n (%)) 9 (28.1%) 6 (21.4%) ns
Plaque volume (mm
3) 35.2 ± 44.9 54.5 ± 62.4 ns
Calcium score 32.1 ± 39.1 44.8 ± 50.6 ns
Number of patients with perfusion defects in SPECT 18 (56.3%) 12 (42.9%) ns
Number of underperfused myocardial segments (median) 3 (9.4%) 3 (10.7%) ns
CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDCT, multi-detector computed tomography; ns, not significant; SPECT, single
photon emission computed tomography.
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hematuria and pyuria.
Discussion
The major finding of this study is the inhibition of
atherosclerosis progression by atorvastatin in SLE
patients as evidenced by MDCT-based calcium scoring.
T oo u rk n o w l e d g e ,i ti st h ef i r s tr e p o r ts h o w i n gs u c ha
beneficial effect of statin therapy in this population at
high risk of life-threatening cardiovascular complica-
tions. The volume of coronary calcified plaques was
stable in the active-treatment group, and increased sig-
nificantly in the placebo group. At the same time, cor-
onary calcium score increased significantly in the
placebo group only.
Patients with SLE suffer from premature atherosclero-
sis. Our study supports previously published data on
high frequency of myocardial perfusion defects in SLE
patients as demonstrated by the SPECT study [26,27].
Perfusion defects were present in 50% of cases, despite
normal ECG recordings at rest and lack of any clinical
symptoms of myocardial ischemia. Predominantly per-
sistent perfusion abnormalities were detected. In most
of the patients, the number of underperfused left ventri-
cle segments was low. However, it has been already
established that the presence of even small perfusion
defects in the SPECT study strongly affects prognosis
[28,29]. Beside the presence of myocardial perfusion
defects, 25% of our asymptomatic SLE patients showed
calcified atherosclerotic changes in their coronary
arteries. It is the most frequent localization of such
changes in SLE, as shown in another study of 50 SLE
patients, where the frequency of atherosclerotic plaques
observed in MDCT were the highest in coronary arteries
(42% of patients with calcifications), followed by carotid
arteries (24% of patients with calcifications) [30]. A
study of 157 SLE patients showed that in subjects with
the mean age of 40 years - comparable with the age of
our patients - the frequency of coronary artery calcifica-
t i o n si s3 0t o4 0 %[ 3 1 ] .T h i sp e r c e n t a g ei sr e l a t i v e l y
higher than in the general population: in the study of
35,388 subjects calcium scores above 10 were observed
in only 10% of cases, and calcium scores above 100 in
2% [32]. Coronary calcium deposits provide an indepen-
dent indication of a short- and long-term risk of cardiac
events, even in patients with normal SPECT results
[33-35].
Our results support also the published data showing
higher frequency of myocardial perfusion abnormalities
detected by SPECT as compared with the frequency of
coronary calcium deposits detected by MDCT in SLE
population [26,27,31]. This might be partially explained
by the fact that antiphospholipid antibodies are asso-
ciated with thrombotic events in coronary beds, rather
than with subclinical atherosclerosis [36]. Thrombosis in
coronary arteries leads to perfusion defects detectable by
SPECT, but not by MDCT. Calcified plaques may
develop in time at the basis of thrombi or may form
due to endothelium dysfunction. In the present study
the patients with perfusion abnormalities despite the
lack of coronary calcifications were observed. On the
other hand, small coronary plaques may have no influ-
ence on the perfusion: the patients with normal perfu-
sion despite small calcium deposits in the arteries were
also observed.
The inhibition of atherosclerosis progression in SLE
patients by atorvastatin seems of major importance for
their prognosis. In a seven-year prospective follow-up
s t u d yi nag r o u po f1 , 1 2 6o t h e r w i s eh e a l t h ys u b j e c t s ,
Chang et al. showed that the risk of myocardial infarc-
tion or the need for revascularization correlated with
the patients calcium score and occurred at higher fre-
quency in subjects with calcium score above 100 [33].
In our study, the mean value of the calcium score was
lower (39.9 ± 50.9) and the follow-up period much
shorter, but the significant progression of atherosclerosis
Table 3 Coronary calcium score, number and volume of coronary plaques in SLE patients from the placebo group and
atorvastatin group at randomization and after one year of treatment
At randomization After one year P
Placebo group, n =3 2
Number of patients with plaques 9 (28.1%) 10 (31.3%) ns
Plaque volume (mm
3) 35.2 ± 44.9 62.9 ± 72.4 < 0.05
Number of plaques 2-13 (median 4) 1-12 (median 5) ns
Calcium score 32.1 ± 39.1 59.5 ± 54.4 < 0.05
Atorvastatin group, n =2 8
Number of patients with plaques 6 (21.4%) 6 (21.4%) ns
Plaque volume (mm
3) 54.5 ± 62.4 51.0 ± 47.6 ns
Number of plaques 2-4 (median 2) 1-8 (median 2) ns
Calcium score 44.8 ± 50.6 54.9 ± 62.5 ns
ns, not significant; SLE, systemic lupus erythematosus.
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85.4% during one year) may have important clinical
implications for patients’ future.
Atorvastatin did not influence myocardial perfusion as
assessed by SPECT. Calcium deposits in coronary
arteries revealed by MDCT were obviously too small to
result in any significant persistent or exercise-induced
perfusion defects.
It has been shown that statins exert not only anti-
lipid, but also marked anti-inflammatory effects [9].
Accordingly, in our study serum concentrations of total
cholesterol, LDL cholesterol, and triglycerides all
decreased after atorvastatin treatment. Importantly, this
was accompanied by the decrease in CRP despite an
unchanged immunosuppressive therapy. It was pre-
viously shown that the magnitude of protection and the
decrease in mortality afforded by statins cannot be
entirely explained by their cholesterol-lowering effect
[10]. A large study of 3,745 patients showed that
patients who have low CRP levels after statin therapy
have better clinical outcome than those with higher
CRP levels, regardless of the resultant level of LDL cho-
lesterol decrease [9]. The ability of atorvastatin to lower
CRP concentrations shown in this study is of major
importance for SLE patients, as an ongoing chronic
inflammation presents as the major mechanism of sys-
temic SLE complications.
Recently, the Lupus Atherosclerosis Prevention Study
has been completed [37], based on the methodology
similar to that described above. The authors found a
greater increase in coronary artery calcium score in the
placebo group, but due to a calcium score increase
observed also in the atorvastatin group, the inter-group
change was not statistically significant. There was, how-
ever, a significant difference in favor of atorvastatin in
the proportion of patients in whom carotid intima-
media thickness improved, stayed the same, or got
worse. Surprisingly, during follow up, a greater decrease
of CRP level was observed in the placebo group as com-
pared with the atorvastatin group.
Statin therapy in SLE may be complicated by the
reported cases of statin-induced lupus-like syndrome
[38-40]. Pathogenic mechanisms may include increased
cellular apoptosis induced by statins [41] and/or direct
immunomodulatory effect of statins on T lymphocytes
[42]. In our patients, no changes typical of any statin-
related adverse events were observed. Liver enzyme and
CPK levels were normal in all active-treated subjects.
There was also no other adverse effects that would
require discontinuation of therapy.
(a)
(b)
aorta
aorta
Figure 1 The examples of multi-detector computed
tomography in a patient from the (a) placebo group at
randomization and (b) after one year. a) At randomization, two
calcified plaques are seen in left anterior descending artery (red
colour) and one calcified plaque in circumflex artery (blue colour).
Plaques volume 156.4 mm
3, calcium score 138.9. b) After one year,
the volume of previously observed plaques increased with the new
calcification in distal part of left anterior descending artery. Plaques
volume 223 mm
3, calcium score 202.5.
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management of SLE patients, because the presence of
atherosclerotic plaques detected by MDCT and myo-
cardial perfusion defects detected by SPECT are strong
predictors of death in other populations of patients
[28,29,33-35]. Possible beneficial effects of statin
treatment on prognosis of SLE patients should, how-
ever, be addressed in future large prospective clinical
trials.
Limitations of the study
Although the most commonly used marker of coronary
atherosclerosis is calcium scoring, we also measured the
volume of calcified plaques in coronary arteries. This is
because a major limitation of Agatson calcium score
estimation is the measurement of calcium deposits area
and density measurement of the calcium (Hounsfield
units, HU) itself. The density is assessed using the
weighting factor in a stepwise manner, that is not linear
or continuous: for calcium measures 130 to 200 HU the
density score is one, for 200 to 300 HU the density
score is two, etc. [21]. Therefore, small HU difference
may yield a major Agatson score difference. Also, its
reproducibility is limited to ± 15 to 20%.
Although coronary calcified plaques are proved to be
responsible for myocardial ischemia and myocardial
infarction, the other mechanisms of coronary flow
abnormalities in SLE population should also be under-
lined. Endothelial damage and/or microthrombosis in
coronary bed related to antiphospholipid autoantibodies
[36,43,44] was discussed above.
Conclusions
The SPECT study showed myocardial perfusion defects
in 50% of SLE patients despite normal ECG recordings
and lack of clinical symptoms of myocardial ischemia.
In addition, 25% of patients showed atherosclerotic pla-
ques in coronary arteries.
Treatment with atorvastatin lead not only to the
decrease of serum lipids and CRP levels, but also to the
limitation of atherosclerosis progression as assessed by
MDCT-based calcium scoring. The definite value of sta-
tin therapy in SLE patients free of clinical symptoms of
Table 4 Persistent and exercise-induced myocardial perfusion defects in SLE patients from placebo group and
atorvastatin group at randomization and after one year of treatment
At randomization After one year P
Placebo group, n =3 2
Number of patients with
persistent perfusion defects
14 (43.8%) 11 (34.3%) ns
Number of persistently underperfused segments 2-5 (median 3) 3-6 (median 3) ns
Number of patients with exercise-induced perfusion defects 4 (12.5%) 6 (18.8%) ns
Number of underperfused
myocardial segments at exercise
1-4 (median 3) 2-3 (median 3) ns
Atorvastatin group, n =2 8
Number of patients with persistent perfusion defects 8 (28.6%) 8 (28.6%) ns
Number of persistently underperfused segments 1-5 (median 3) 2-6 (median 3) ns
Number of patients with exercise-induced perfusion defects 4 (14.3%) 5 (17.9%) ns
Number of underperfused myocardial segments at exercise 2-4 (median 3) 3-6 (median 3) ns
ns, not significant; SLE, systemic lupus erythematosus.
Table 5 Biochemical data and SLEDAI score in SLE
patients from atorvastatin group and from placebo
group at randomization and after one year of treatment
At randomization After one year P
Atorvastatin group, n =2 8
Total cholesterol (mmol/l) 5.1 ± 1.2 4.4 ± 0.7 < 0.05
LDL cholestrol (mmol/l) 2.9 ± 1.0 2.3 ± 0.6 < 0.05
HDL cholesterol (mmol/l) 1.4 ± 0.3 1.4 ± 0.3 ns
Triglycerides (mmol/l) 1.6 ± 0.6 1.2 ± 0.5 < 0.05
CRP (mg/l) 4.4 ± 4.1 2.7 ± 1.7 < 0.05
ALT (IU/l) 23.9 ± 6.7 22.4 ± 6.9 ns
AST (IU/l) 22.9 ± 3.7 31.5 ± 6.2 ns
CPK (IU/l) 70.0 ± 78.2 62.9 ± 47.2 ns
SLEDAI 2-20 (median 4) 0-20 (median 4) ns
Placebo group, n =3 2
Total cholesterol (mmol/l) 4.5 ± 0.8 4.5 ± 0.7 ns
LDL cholestrol (mmol/l) 2.6 ± 0.8 2.6 ± 0.8 ns
HDL cholesterol (mmol/l) 1.4 ± 0.3 1.4 ± 0.3 ns
Triglycerides (mmol/l) 1.2 ± 0.5 1.3 ± 0.6 ns
CRP (mg/l) 4.0 ± 8.9 3.9 ± 5.1 ns
ALT (IU/l) 27.1 ± 8.6 39.1 ± 51.4* ns
AST (IU/l) 26.1 ± 6.2 40.2 ± 56.6* ns
CPK (IU/l) 53.2 ± 37.5 71.2 ± 57.2 ns
SLEDAI 0-12 (median 4) 0-12 (median 2) ns
* in one patient increased ALT (248 IU/l) and AST (273 IU/l) levels were
observed
CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; CPK, creatine phosphokinase; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; ns, not significant; SLE, systemic lupus
erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
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spective clinical trials.
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